Nasdaq · Biotech stocks database
ADRX — ADARx Pharmaceuticals Inc. ☆
ADRX (ADARx Pharmaceuticals Inc.) stock: $16.52, $1.76B market cap, $924.3M cash, $840.1M EV, $2.01B fully diluted market cap. Lead program: ADX-324 (Hereditary Angioedema), Phase 3. Data from Fully Diluted's biotech stocks database.
Overview
Catalysts
Assets
Pipeline
Trials
Holders
News
What they do
We are a late-clinical stage biotechnology company focused on developing next-generation siRNA therapeutics designed to treat a broad spectrum of diseases. We are focused on advancing and expanding our pipeline of highly potent, selective and durable double-stranded oligonucleotides (siRNA) therapeutic candidates, including three clinical-stage programs and two advanced preclinical programs.
Source: S-1 FY2026 via SEC EDGAR
Balance sheet
Cash $924.3M Debt $0.0M Net cash $924.3M Enterprise value $840.1M Basic shares 106.8M shares Fully diluted shares 121.7M shares Fully diluted market cap $2,010.1M Cash per share $8.65
Cash figures as of 2026-06-30. Database snapshot: 2026-10-30.
Share structure
Cap table as of 2026-09-28.
Price history Loading ADRX daily closes…
Loading price history…
Asset data not yet available for this company.
Pipeline Lead drug ADX-324 Lead indication Hereditary Angioedema Lead phase Phase 3 Active trials 9
No active ClinicalTrials.gov trials matched to this company as sponsor or collaborator.
Specialist fund holders Tracked specialist funds: ADAR1 Capital Management, Aisling Capital, Ally Bridge Group, Avoro Capital Advisors, BVF Partners, Baker Bros. Advisors, Boxer Capital, Braidwell LP, Casdin Capital, Cormorant Asset Management, DAFNA Capital, Deerfield Management, EcoR1 Capital, Frazier Life Sciences, Great Point Partners, Ikarian Capital, Logos Global Management, OrbiMed Advisors, Perceptive Advisors, RA Capital Management, RTW Investments, Sphera Biotech, Stonepine Capital, Tang Capital Partners, Vivo Capital.
None of the tracked specialist funds reported a position in the latest 13F snapshot.
Fully Diluted · Free biotech stocks database. Figures are sourced from SEC filings and company disclosures; not investment advice.